Blood Levels of Nitric Oxide,C-Reactive Protein,and Tumor Necrosis Factor-α Are Upregulated in Patients with Malignancy-Associated Hypercoagulable State: Pathophysiologic Implications

Abstract

Endogenous generation of nitric oxide (NO) plays an important role in the regulation of cardiovascular and inflammatory responses. This mediator is synthesized by a family of enzymes collectively known as NO synthase. Several isoforms of this enzyme have been identified and can be grouped as constitutive or inducible. Increased production of NO is reported in several inflammatory disorders, such as sepsis, arthritis, thrombotic thrombocytopenic purpura (TTP), and antiphospholipid syndrome. In addition, NO upregulates cyclo-oxygenase-2 and synthesis of several other inflammatory cytokines. Inflammation and thrombotic complications are usually associated with malignancy. Earlier reports indicate the upregulation of tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and tissue factor (TF) in patients with malignancy. To determine the relationship between inflammatory cytokines and NO in cancer patients with hypercoagulable states, baseline plasma samples from 160 patients with confirmed malignancy and hypercoagulable state were analyzed for NO levels. A chemical method based on a chemiluminescent reaction between NO and ozone using a highly sensitive gas phase NO analyzer was used. CRP, TF, and TNF-α were measured using enzyme-linked immunosorbent assay methods. Of the 160 patients who were plasma tested, the baseline NO levels ranged from 13.7 to 98.6 μM (63.1±15.9 μM, mean±SD) in contrast to age-matched control, which ranged from 9.1 to 34.6 μM (19.8±6.2 μM, mean±SD, n=138). Cancer patients also showed marked variations in the NO levels. Eighteen of 60 cancer patients exhibited greater than 60 μM NO levels. The CRP, TNF-α and TF were also significantly elevated. A correlation between CRP (r²=0.73) and NO levels was noted in cancer patients with hypercoagulable state. These data suggest that the pathogenesis associated with malignancy/hypercoagulable state is associated with an inflammatory component. In addition, the observed hemodynamic changes in some of the cancer patients may be due to increased NO production.

Keywords

Nitric oxide Tumor necrosis factor-α C-reactive protein Hypercoagulable state Malignancy

References

Knowles RG , Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298:249.

Sheehan M , Wong HR . Yet another potential role for nitric oxide in the pathopysiology of septic shock. Crit Care Med 2002;30(6):1393.

Yki-Jarvinen H , Bergholm R , Leirisalo-Repo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis 2003;62(7):630.

Porta C , Buggia I , Bonami I , et al. Nitrite and and nitrate plasma levels, as a markers of nitric oxide synthesis, in thrombotic thrombocytopenic purpura (TTP). A case-control study. Hematology 1996;1:239.

Porta C , Buggia I , Bonomi I , et al. Nitrite and nitrate plasma levels, as markers of nitric oxide synthesis, in antiphospholipid antibodies-related conditions and in thrombotic thrombocytopenic purpura. Thromb Haemost 1997;78(2):965.

Szabo C , Ohshima H. DNA damage induced by peroxynitrate: Subsequent biological effects. Nitric Oxide 1997;1(5):373.

Jadeski LC , Chakraborty C , Lala PK . Role of nitric oxide in tumor progression with special reference to a murine breast cancer model. Can J Physiol Pharmacol 2002;80:125.

Liu Q , Chan ST , Mahendran R. Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis 2003;24(4):637.

Fehsel K , Plewe D , Kolb-Bachofen V. Nitric oxide-induced expression of C-reactive protein in islet cells as a very early marker for islet stress in the rat pancreas. Nitric Oxide 1997;1(3):254.

10.

Chhatwal VJS , Moochhala SM , Chan STF , Ngoi SS . Nitric oxide and cancer. Med Hypoth 1996;46:21.

11.

Chhatwal VJS , Ngoi SS , Chan STF , et al. Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding peritumoral normal mucosa. Carcinogenesis 1994;15:2081.

12.

Thomsen LL , Lawton FG , Knowles RG , et al. Nitric oxide synthase activity in human gynecologic cancer. Cancer Res 1994;54:1352.

13.

Moncada S , Higgs EA . The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002.

14.

Kaiser B , Hoppensteadt DA , Fareed J. Tissue factor pathway inhibitor: An update of potential implications in the treatment of cardiovascular disorders. Exp Opin Invest Drugs 2001;10(11):1925.

15.

Grover R , Zaccardelli D , Colice G , et al. An open-label dose escalation study of the nitric oxide synthase inhibitor L-Ng-methylarginine hydrochloride (546C88) in patients with septic shock. Crit Care Med 1999;27:913.

16.

Cella G , Sbarai A , Mazzaro G , et al. Tissue factor pathway inhibitor release induced by defibrotide and heparins. Clin Appl Thromb Hemost 2001;7(3):225.

17.

Horie S , Sayuri H , Hamuro T , et al. Oxidazed Low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein. Thromb Haemost 2002;87:80.

18.

Mechtcheriakova D , Schabbauer G , Lucerna M , et al. Specificity, diversity, and convergence in VEGF and TNF-α signaling events leading to tissue factor upregulation via EGR-1 in endothelial cells. FASEB J 2001;15:230.

19.

Terry CM , Callahan KS . Protein kinase C regulates cytokine-induced tissue factor transcription and procoagulant activity in human endothelial cells. J Lab Clin Med 1996;127:81.

20.

Alban S. Molecular weight-dependent influence of heparins on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost 2001;27(5):503.

21.

22.

Tsopanoglou NE , Pipili-Synetos E , Maragoudakis ME . Thrombin promotes angiogenesis by a mechanism independent of fibrin formation Am J Physiol 1993;264:C1302.

23.

Tsopanoglou NE , Maragoudakis ME . On the mechanism of thrombin-induced angiogenesis: Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 1999;274:23969.

24.

Ollivier V , Bentolila S , Chabbar J , et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91:2698.

25.

Abe K , Shoji M , Chen J , et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmin tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663.

26.

O’Reilly MS , Pirie-Shepherd S , Lane WS , et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926.